CN112210085A - 腐植酸/黄腐酸三萜皂甙共聚物片剂或粉剂 - Google Patents
腐植酸/黄腐酸三萜皂甙共聚物片剂或粉剂 Download PDFInfo
- Publication number
- CN112210085A CN112210085A CN201910587266.3A CN201910587266A CN112210085A CN 112210085 A CN112210085 A CN 112210085A CN 201910587266 A CN201910587266 A CN 201910587266A CN 112210085 A CN112210085 A CN 112210085A
- Authority
- CN
- China
- Prior art keywords
- acid
- humic acid
- triterpenoid saponin
- powder
- copolymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004021 humic acid Substances 0.000 title claims abstract description 78
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 title claims abstract description 73
- FCYKAQOGGFGCMD-UHFFFAOYSA-N Fulvic acid Natural products O1C2=CC(O)=C(O)C(C(O)=O)=C2C(=O)C2=C1CC(C)(O)OC2 FCYKAQOGGFGCMD-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 229940095100 fulvic acid Drugs 0.000 title claims abstract description 52
- 239000002509 fulvic acid Substances 0.000 title claims abstract description 52
- 229920001577 copolymer Polymers 0.000 title claims abstract description 28
- 239000000843 powder Substances 0.000 title claims abstract description 25
- PUKLDDOGISCFCP-JSQCKWNTSA-N 21-Deoxycortisone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2=O PUKLDDOGISCFCP-JSQCKWNTSA-N 0.000 claims abstract description 38
- 150000008130 triterpenoid saponins Chemical class 0.000 claims abstract description 20
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000002994 raw material Substances 0.000 claims abstract description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 9
- -1 fulvic acid triterpenoid saponin compound Chemical class 0.000 claims abstract description 7
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 7
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 7
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 7
- 229930182490 saponin Natural products 0.000 claims abstract description 7
- 239000003054 catalyst Substances 0.000 claims abstract description 5
- 238000004090 dissolution Methods 0.000 claims abstract description 3
- 230000020477 pH reduction Effects 0.000 claims abstract description 3
- 239000011347 resin Substances 0.000 claims abstract description 3
- 229920005989 resin Polymers 0.000 claims abstract description 3
- 229930182470 glycoside Natural products 0.000 claims abstract 2
- 150000002338 glycosides Chemical group 0.000 claims abstract 2
- 238000007334 copolymerization reaction Methods 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000005494 condensation Effects 0.000 claims description 7
- 238000009833 condensation Methods 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 238000003916 acid precipitation Methods 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- ORXJMBXYSGGCHG-UHFFFAOYSA-N dimethyl 2-methoxypropanedioate Chemical compound COC(=O)C(OC)C(=O)OC ORXJMBXYSGGCHG-UHFFFAOYSA-N 0.000 claims 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000003381 solubilizing effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 244000144972 livestock Species 0.000 abstract description 11
- 244000144977 poultry Species 0.000 abstract description 8
- 239000003077 lignite Substances 0.000 abstract description 7
- 239000003415 peat Substances 0.000 abstract description 7
- 240000001548 Camellia japonica Species 0.000 abstract description 6
- 206010012735 Diarrhoea Diseases 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 abstract description 6
- 239000003245 coal Substances 0.000 abstract description 5
- 239000003814 drug Substances 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 5
- 239000003674 animal food additive Substances 0.000 abstract description 4
- 150000007949 saponins Chemical class 0.000 abstract description 4
- 238000001694 spray drying Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 208000001848 dysentery Diseases 0.000 abstract description 3
- 230000036039 immunity Effects 0.000 abstract description 3
- 229960005322 streptomycin Drugs 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 239000000273 veterinary drug Substances 0.000 abstract description 3
- 150000001768 cations Chemical class 0.000 abstract description 2
- 230000036541 health Effects 0.000 abstract description 2
- 208000004396 mastitis Diseases 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 108010001478 Bacitracin Proteins 0.000 abstract 1
- 208000005577 Gastroenteritis Diseases 0.000 abstract 1
- TURHTASYUMWZCC-UHFFFAOYSA-N Olaquindox [BAN:INN] Chemical compound C1=CC=C2N([O-])C(C)=C(C(=O)NCCO)[N+](=O)C2=C1 TURHTASYUMWZCC-UHFFFAOYSA-N 0.000 abstract 1
- 208000007107 Stomach Ulcer Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229960005364 bacitracin zinc Drugs 0.000 abstract 1
- 239000006184 cosolvent Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 201000005917 gastric ulcer Diseases 0.000 abstract 1
- 238000005469 granulation Methods 0.000 abstract 1
- 230000003179 granulation Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000004877 mucosa Anatomy 0.000 abstract 1
- 229950010210 olaquindox Drugs 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 238000005728 strengthening Methods 0.000 abstract 1
- 208000000143 urethritis Diseases 0.000 abstract 1
- UCRLQOPRDMGYOA-DFTDUNEMSA-L zinc;(4r)-4-[[(2s)-2-[[(4r)-2-[(1s,2s)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carbonyl]amino]-4-methylpentanoyl]amino]-5-[[(2s,3s)-1-[[(3s,6r,9s,12r,15s,18r,21s)-3-(2-amino-2-oxoethyl)-18-(3-aminopropyl)-12-benzyl-15-[(2s)-butan-2-yl]-6-(carbox Chemical compound [Zn+2].C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC([O-])=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@H](CC([O-])=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 UCRLQOPRDMGYOA-DFTDUNEMSA-L 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 239000003242 anti bacterial agent Substances 0.000 description 12
- 229940088710 antibiotic agent Drugs 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 7
- 239000011734 sodium Substances 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 235000018597 common camellia Nutrition 0.000 description 5
- 235000017709 saponins Nutrition 0.000 description 5
- 241001122767 Theaceae Species 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 238000004537 pulping Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229930182493 triterpene saponin Natural products 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- XBZYWSMVVKYHQN-MYPRUECHSA-N (4as,6as,6br,8ar,9r,10s,12ar,12br,14bs)-10-hydroxy-2,2,6a,6b,9,12a-hexamethyl-9-[(sulfooxy)methyl]-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid Chemical compound C1C[C@H](O)[C@@](C)(COS(O)(=O)=O)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C XBZYWSMVVKYHQN-MYPRUECHSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012643 polycondensation polymerization Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H6/00—Macromolecular compounds derived from lignin, e.g. tannins, humic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Communicable Diseases (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了腐植酸/黄腐酸三萜皂甙共聚物片剂或粉剂的制作方法,它包括腐植酸三萜皂甙共聚物片剂或粉剂,黄腐酸三萜皂甙共聚物片剂或粉剂,腐植酸/黄腐酸三萜皂甙复合物片剂或粉剂。并按以下方法制备而成:采用泥炭(或草炭),褐煤,风化煤为原料的矿源腐植酸,用“碱溶酸析”和阳离子“树脂交换法”获得提纯腐植酸或黄腐酸溶液,再与山茶科植物种中的皂苷/寡糖共聚,在催化剂和助溶剂的作用下,腐植酸中的芳环酚羟基或羧基与三萜皂甙中苷环上的醛羟基或寡聚糖脱水缩合,形成腐植酸氧苷连接的三萜皂甙/共聚物及其他多种活性成份的复合物,再经喷雾干噪或制粒工序而得到的片剂或粉剂;本发明改变了腐植酸或黄腐酸的单一组份功能,提高了对胃肠粘膜的保护和修复作用,对畜禽胃溃疡,肠胃炎,乳腺炎,尿路炎,腹泻,痢疾等常见病有明显效果;同时对抗感染,抗应急,抗风湿,增強机体免疫力等,有一定功效;而且引入了皂苷和寡糖的药用价值,优势互补,本发明可取代喹乙醇、杆菌肽锌,链霉素等常用化学药物饲料添加剂,是一种新的天然生物兽药保健产品。
Description
技术领域
本发明涉及一种采用矿源腐植酸、黄腐酸与山茶科植物种子中”三萜皂甙”活性物缩共聚的方式,形成“腐植酸/黄腐酸三萜皂甙共聚物”,然后再制成片剂或粉剂,属生物化学领域。
背景技术
腐植酸(Humic Acid简称HA)、黄腐酸(Fulivc Acid简称FA),是从含有HA的褐煤,泥炭,风化煤中提取的一种多元芳香羧酸有机混合物,对畜禽肠胃炎,仔豬/仔鸡白痢,腹泻,乳腺炎,消化不良,发育迟缓,提高机体免疫力等,都有明显的作用和效果;
九十年代,黑龙江首次批准了畜用“腐植酸钠”制剂;九八年上海畜牧局药政处批准了“腐植酸钠”饲料添剂。因此,腐植酸/黄腐酸在畜牧/兽医领域中的应用,正式走向市场,其医疗效果得到了肯定。
但是,单一的腐植酸、黄腐酸在治疗畜禽疾病时,对病原微生物的抑制和杀灭效果,並不理想;为了开发一种代抗菌素的腐植酸中药制剂,我们在多年的试验/筛选中,在山茶科植物种子中,找到了一种天然活性物质“三萜皂甙(或皂苷)”,经试验,本品对多种病源微生物有抑制或杀灭作用,它与腐植酸缩合共聚后,提高了单一品种的抗病效果,是一种多功能的植物源兽药制剂,可代替常用抗菌素。
上海通微生物技术公司高级工程师张常书,1998年在上海众望饲料公司研发的“黄腐酸三萜皂甙共聚物”经多次试验,在治疗仔豬白痢,腹泻等常见病,优于抗菌素,而且,促长,抗病,料肉比,成活率等优于常用化学药物;应用研究成果,已达到国内领先水平,属国内首创,并获得上海市高新技术成果转化项目!同时,还获得上海创造发明金奖!
腐植酸与三萜皂甙,在一定温度下脱羧缩合,形成“腐植酸皂甙共聚物”,二者优势互补,药用和保健价值倍增,为我国开发成功了一个多功能的纯天然的畜禽用生物兽药,代替抗生素,对畜禽常见病的治疗,具有十分重大的意义!
发明内容
本发明采用矿源腐植酸或黄腐酸与山茶种子中的----三萜皂甙缩合共聚,生成“腐植酸三萜皂甙共聚物”;用于畜禽常见病治疗,可代替抗菌素,大大提高了单一品种的医疗保健效果,为我国发明创新了一个多功能的兽药生物制剂。
本发明是通过以下技术方案实现的:
一种“腐植酸/黄腐酸三萜皂甙共聚物片剂或粉剂”,是以含腐植酸或黄腐酸的褐煤,风化煤,泥炭(或草炭)为原料,经“碱提酸析”(常规方法)而获得的提纯腐植酸(HA),或黄腐酸(FA),分子示性式R-COOH;分子量1000----5000,分子结构复杂的芳香羧酸混合物;
上述提纯腐植酸R-COOH,加氢氧化钠NaOH 10%,加水为HA的5倍,在80-90c度下加热搅拌30-40分钟,生成腐植酸钠R-COONa,再用“酸析法”,PH<2分离出黄腐酸FA和腐植酸HA两种溶液,可以制成两种(HA和FA)三萜皂甙共聚物;
用山茶籽榨油后,粉碎,加5倍无离子水,搅拌打浆后,加温80-90c度,搅拌活化2-3小时后,挤压除渣,得到60%的三萜皂甙与寡聚糖混合液(还含其他活性物质);
将腐植酸或黄腐酸溶液50%,加入三萜皂甙抽提液50%(1∶1,二者可调),加热到80-90c度,用0.1%的甲醛作促进剂和0.5%的NaOH作增溶剂,搅拌缩合反应2-3h,HA上的R-COOH与三萜皂甙中的醛羟基或羧基脱水缩合,形成腐植酸或黄腐酸缩合共聚物及其他多种活性成份的复合液;再经浓缩干燥后,制成片剂或粉剂。
本发明还公开了一种“腐植酸/黄腐酸三萜皂甙共聚物片剂或粉剂”的制备方法;
(1)将含有HA的原料(褐煤,风化煤或泥炭),粉碎到<40目,加水5倍,加HONa(占总量)10%,加温到80-90c度,抽提得到总HA;再用HCL调PH值≤2,离心除去沉淀物(棕、黑HA)得FA液;如果不用酸处理,即是总HA钠溶液。
(2)将山茶籽榨油后的饼渣,粉碎,加无离子水5倍,用打浆机打浆后,加温80-90c度、搅拌抽提2-3小时后,挤压除渣,得60%的三萜皂甙与寡糖混合物(还含其他活性物质)的提取液;
(3)利用上述复合溶液与两种腐植酸液中的酚羟基(R-OH)或羧基(R-COOH),在80-90c度和0.1%甲醛的催化和0.5%NaOH增溶作用下,在PH 7.2一7.5的范围内进行脱水缩合共聚,可得到2种“腐植酸或黄腐酸/三萜皂甙共聚复合液”,经喷雾干燥可得粉剂,再经压片处理后可制成片剂。
本发明制备的“腐植酸/黄腐酸三萜皂甙共聚物片剂或粉剂为棕灰色,PH为7-8,可溶于水。
本发明涉及的原料和试剂,经市售或加工可得;
本发明的有益效果为:
(1)提高了HA、FA分子的分子量和聚合度,生成新的高分子腐植酸/寡糖/皂甙聚合物,对动物肠、胃粘膜溃疡,畜禽赤/白痢,肠炎,腹泻等,具有良好的治疗或修复作用;
(2)提高了单一品种的多功能性,大大提高了畜禽医疗、保健效果;
(3)广泛用于各种畜禽常见病防治,代替抗菌素用于饲料添加剂,提高免疫力等,具有良好效果;
具体实施方式
以下结合实施例,对本发明做进一步说明;这些实施例仅用于说明本发明,而不用于限制本发明的保护范围。
实施例1
腐植酸/三萜皂贰共聚物片剂或粉剂的制备。
一、HA原料选择:本发明是以含腐植酸或黄腐酸的褐煤,风化煤,泥炭(或草炭)为原料,其中风化褐煤最好;HA或FA含量应>50%以上为优质原料;
二、山茶籽原料选择:本发明是以山茶科的油茶籽为原料,南方各地野生或人工栽培均可!
三、制备工艺:
(1)腐植酸提取液,采用含50%以上HA的风化褐煤,加无离子水5倍和10%的HONa,加热到80-90c度搅拌反应30分钟后,沉淀离心,除去水不溶物,得总HA钠溶液;
(2)采用油茶饼,粉碎(<3mm),加水5倍,打浆,加热80-90c度x3h后,挤压、过滤,得三萜皂甙复合溶液;
(3)将上述两种溶液,按照1∶1(可调)的比例,加入0.1%甲醛催化剂和0.5%NaOH增溶剂,加温到80-90c度,在PH7.2-7.5的范囲内进行脱水缩合/共聚2-3h,再喷雾干燥可得腐植酸三萜皂甙共聚物粉剂,再经压片造粒,可得片剂或颗粒。
四、产品分析:本品按腐植酸三萜皂甙共聚物,其主要特征是分子量增大,粘度提高,以“乌氏粘度测试法”,测得腐植酸特性粘度为缩合共聚后的特性粘度为较HA原粘度提高2.08倍;按HG/T 3278-1987标准测得总有机物为83.6%,腐植酸35.3%PH7.6;用“比色法”,或“薄层扫描法”测得三萜皂甙32.7%;达到了腐植酸三萜皂或复合共聚的目的。
实施利2
黄腐酸/三萜皂甙共聚物片剂或粉剂的制备
将腐植酸原料改为含有50%以上的黄腐酸原料,用“碱溶酸析法”或阳离子“树脂交換法”提取FA溶液;取100kgFA液,与100Kg三萜皂甫液缩合,按1∶1的比例(可调),加入0.1%甲醛的催化剂和0.5-0.3%NaOH增溶剂,加温到80-90c度,在PH7.2一7.5的范围内进行脱水缩合/共聚2-3h,再喷雾干燥或制粒可得黄腐酸/三萜皂甙共聚物片剂或粉剂。
五、产品分析:本品按腐植酸/三萜皂甙共聚物的主要特征是分子量增大,特性粘度提高,以“乌氏粘度测试法”,测得黄腐酸特性粘度为共聚后的特性粘度为较HA原粘度提高了2.4倍。按HG/T 3278-1987标准测得总有机物为78.3%,黄腐酸≥34.5%;用“比色法”,或“薄层扫描法”测得三萜皂甙≥32.5%,PH 7.2。达到了黄腐酸三萜皂甙共聚的目的。
实施例3
(1)采用上述实施例1或2提取的腐植酸钠或黄腐酸液;
(2)采用上述山茶提取三萜皂甙复合溶液;
(3)将上述两种溶液,按照1∶1(可调)的比例,不经缩合反应,直接进行混溶,可得“腐植酸或黄腐酸/三萜皂甙复合液”。
(4)将上述复合液用喷雾或刮板干燥后得“腐植酸或黄腐酸/三萜皂甙”粉剂,再经制粒工艺,得到片剂或颗粒剂。
产品分析:本品的主要特征是腐植酸/黄腐酸和三萜皂甙的复合物,易溶于水。按照腐植酸钠HG/T 3278-1987标准,测得产品中含腐植酸为54.6%,PH7.8;用“比色法”,或“薄层扫描法”,测得三萜皂甙的含量为31.8%,黄腐酸型为35.6%,PH 7.6。
效果试验:
1.腐植酸/黄腐酸三萜皂贰共聚物片剂或粉剂实用效果。
2012年8-12月,发明人在上海众望词料和上海文荣集团特种养殖埸,枫泾养猪埸,松江养鸡场等,进行
试验;用本品与黄腐酸,抗生素(庆大霉素和链霉素)进行对比试验,其试验结果如下:
表1 代抗菌素防治小豬腹泻试验
注:抗菌素为链霉素+庆大霉素,因常用/产生了抗药性,治愈率很低。
表2 代替仔豬全价饲料中的抗菌素
表3 代抗菌素饲料/中豬防治效果
注:本品在饲料中添加0.1%,饲养1个月后的中猪,腹泻发病效果观查
表4 代抗菌素对肉猪饲养各项指标的影响
注:本组试验是上述表3试验的延续
表5 代抗菌素在肉鸡饲养中的效果
注:将本品在饲料中添加0.1%,喂养30天的结果
表6 代抗菌素在雏鸡饲养中的效果
注:将本品在饲料中添加0.1%,喂养30天的结果。
Claims (3)
1.腐植酸/黄腐酸三萜皂甙共聚物,其特征在于:利用含有腐植酸或黄腐酸的矿物原料,经碱溶酸析提纯后得到的总腐植酸或黄腐酸;利用腐植酸芳环中的酚羟基或羧基(R-OH或R-COOH)与三萜皂甙中的醛羟基或寡聚糖上的羟基[(C6H10O5)n-OH],在催化剂和增溶剂的作用下,脱水缩合,并以苷键(-C-)的方式连接,生成“腐植酸/黄腐酸皂甙多糖共聚物的粉剂或片剂。
2.一种利用权利要求1中所述的总腐植酸,再用PH=2的盐酸(HCl)“酸析沉淀”或用阳离子“树脂交换法”,提取黄腐酸,再按权利要求1中的共聚方法,与三萜皂甙在催化剂和增溶的作用下,脱水缩合,即可得到“黄腐酸/三萜皂甙共聚物”粉剂或片剂。
3.一种直接利用腐植酸/黄腐酸与三萜皂甙直接复合配制的粉剂或片剂,虽然没有参加缩合共聚反应,而是直接混合形式,二者也产生了优势互补作用,发挥了两者的多功能,大大提高了单一药用价值。因此,将腐植酸或黄腐酸,直接与三萜皂甙(苷)按一定比例复配,得到的“腐植酸或黄腐酸/三萜皂甙复合物粉剂或片剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910587266.3A CN112210085A (zh) | 2019-06-24 | 2019-06-24 | 腐植酸/黄腐酸三萜皂甙共聚物片剂或粉剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910587266.3A CN112210085A (zh) | 2019-06-24 | 2019-06-24 | 腐植酸/黄腐酸三萜皂甙共聚物片剂或粉剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112210085A true CN112210085A (zh) | 2021-01-12 |
Family
ID=74047041
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910587266.3A Pending CN112210085A (zh) | 2019-06-24 | 2019-06-24 | 腐植酸/黄腐酸三萜皂甙共聚物片剂或粉剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112210085A (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1346600A (zh) * | 2001-04-24 | 2002-05-01 | 上海众望饲料有限公司 | 无抗菌素畜禽绿色饲料生产工艺及产品 |
US20070190004A1 (en) * | 2004-03-18 | 2007-08-16 | Dirk Bockmuhl | Substances with a probiotic action used in deodorants |
EP2322138A2 (de) * | 2009-09-02 | 2011-05-18 | Henkel AG & Co. KGaA | Antimikrobielle Formulierung |
-
2019
- 2019-06-24 CN CN201910587266.3A patent/CN112210085A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1346600A (zh) * | 2001-04-24 | 2002-05-01 | 上海众望饲料有限公司 | 无抗菌素畜禽绿色饲料生产工艺及产品 |
US20070190004A1 (en) * | 2004-03-18 | 2007-08-16 | Dirk Bockmuhl | Substances with a probiotic action used in deodorants |
EP2322138A2 (de) * | 2009-09-02 | 2011-05-18 | Henkel AG & Co. KGaA | Antimikrobielle Formulierung |
Non-Patent Citations (2)
Title |
---|
张常书: "无抗菌素(绿色)饲料及添加剂的开发应用", 《腐植酸》 * |
顾学裘主编: "《药物制剂注解》", 31 May 1983 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103355545B (zh) | 一种发酵型植物性断奶仔猪饲料添加剂 | |
CN101417008A (zh) | 作为中兽药复方制剂的注射用双黄连及其制备工艺与应用 | |
CN105287790B (zh) | 一种鸡矢藤提取物及其应用 | |
AU2021100021A4 (en) | Plant feed additive for preventing and treating diarrhea of weaned piglets and preparation method | |
CN103432158A (zh) | 一种防治猪腹泻的多糖复合剂及用途 | |
CN107173609A (zh) | 一种用于防治家禽腹泻的中草药饲料添加剂 | |
CN106359849B (zh) | 一种含腐植酸螯合微量元素的发酵饲料及其制备方法 | |
CN112335796A (zh) | 一种含有螺旋藻多肽的组合物及其应用 | |
CN103053863B (zh) | 一种具有提高免疫力和除臭效果的猪用饲料添加剂 | |
CN112210085A (zh) | 腐植酸/黄腐酸三萜皂甙共聚物片剂或粉剂 | |
CN102895355A (zh) | 一种治疗家畜腹泻中药注射剂及其制备方法 | |
CN116391806B (zh) | 断奶仔猪用包被单宁酸制剂及其制备方法和用途 | |
CN103621798B (zh) | 利用生活垃圾制备的饲料及其制备方法 | |
CN113521262B (zh) | 一种具有抗炎效果的溶菌酶制剂 | |
KR100962236B1 (ko) | 천연약용식물과 난황항체를 이용한 양돈용 사료첨가제 및그 제조방법 | |
CN101879238A (zh) | 一种预防和治疗鸡大肠杆菌病的药物组合物及其制备方法 | |
CN107494905A (zh) | 一种植物源抑菌剂的制备方法 | |
CN104522395A (zh) | 黄粉虫粪生产牛、羊饲料的方法 | |
CN113143980A (zh) | 一种兽用卷柏混悬型颗粒剂处方及制备工艺 | |
CN112618692B (zh) | 一种防治仔猪黄白痢的中药组合物及其制备方法和用途 | |
CN117982594B (zh) | 一种杜仲和石斛共提物及其提取方法 | |
CN117179169B (zh) | 一种基于多叶勾儿茶提取物的饲料添加剂及其制备方法 | |
CN109731044B (zh) | 一种治疗禽肠道感染的中药复方颗粒及其制备方法 | |
CN115845004B (zh) | 一种用于治疗猪腹泻的中药微囊及其制备方法 | |
CN101001637A (zh) | 具有促生长活性的芍药属植物及其提取物在兽医药物和畜牧学中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210112 |